Mark Miglarese

1.3k total citations
31 papers, 960 citations indexed

About

Mark Miglarese is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Mark Miglarese has authored 31 papers receiving a total of 960 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 12 papers in Cancer Research and 10 papers in Oncology. Recurrent topics in Mark Miglarese's work include Cancer, Hypoxia, and Metabolism (6 papers), PI3K/AKT/mTOR signaling in cancer (6 papers) and Growth Hormone and Insulin-like Growth Factors (6 papers). Mark Miglarese is often cited by papers focused on Cancer, Hypoxia, and Metabolism (6 papers), PI3K/AKT/mTOR signaling in cancer (6 papers) and Growth Hormone and Insulin-like Growth Factors (6 papers). Mark Miglarese collaborates with scholars based in United States, Germany and United Kingdom. Mark Miglarese's co-authors include David Epstein, Elizabeth Buck, Alexandra Eyzaguirre, Maryland Rosenfeld-Franklin, Sharon Barr, Timothy P. Bender, Neil W. Gibson, Eric Brown, Jonathan A. Pachter and Kenneth K. Iwata and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Mark Miglarese

29 papers receiving 941 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Miglarese United States	12	689	375	225	193	143	31	960
P.M. Martin France	17	367 0.5×	357 1.0×	170 0.8×	82 0.4×	118 0.8×	59	895
Isere Kuiatse United States	16	682 1.0×	268 0.7×	172 0.8×	169 0.9×	40 0.3×	36	946
H E Zhau United States	12	568 0.8×	348 0.9×	335 1.5×	45 0.2×	305 2.1×	16	1.0k
Colin R. Lindsay United Kingdom	20	580 0.8×	714 1.9×	398 1.8×	101 0.5×	465 3.3×	68	1.4k
Stacey M. Bagby United States	21	568 0.8×	516 1.4×	242 1.1×	41 0.2×	158 1.1×	62	1.1k
Lou Savas United States	7	548 0.8×	145 0.4×	173 0.8×	69 0.4×	233 1.6×	10	822
Lisa E. Humphrey United States	17	498 0.7×	442 1.2×	112 0.5×	65 0.3×	100 0.7×	23	783
Richard K. Rosenberg United States	9	792 1.1×	853 2.3×	340 1.5×	48 0.2×	260 1.8×	11	1.4k
Ann Mangelsdorf Soderquist United States	10	662 1.0×	274 0.7×	89 0.4×	175 0.9×	54 0.4×	13	932
Rachel V. Pearline United States	5	756 1.1×	343 0.9×	168 0.7×	26 0.1×	135 0.9×	7	976

Countries citing papers authored by Mark Miglarese

Since Specialization

Citations

This map shows the geographic impact of Mark Miglarese's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Miglarese with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Miglarese more than expected).

Fields of papers citing papers by Mark Miglarese

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Miglarese. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Miglarese. The network helps show where Mark Miglarese may publish in the future.

Co-authorship network of co-authors of Mark Miglarese

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Miglarese. A scholar is included among the top collaborators of Mark Miglarese based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Miglarese. Mark Miglarese is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Ming, Nicolas Stransky, Mark Miglarese, et al.. (2025). Predicting ROS1 and ALK fusions in NSCLC from H&E slides with a two-step vision transformer approach. npj Precision Oncology. 9(1). 266–266. 1 indexed citations

Sima, Chao, Matthew Rosenow, Teresa L. Tinder, et al.. (2020). Abstract 5165: Novel approach to colorectal cancer drug target discovery in human FFPE tissue using the Adaptive Dynamic Artificial Polyligand Targeting System. Cancer Research. 80(16_Supplement). 5165–5165.

Pannu, Vaishali, Matthew Rosenow, Daniel Magee, et al.. (2019). Translocation of a Cell Surface Spliceosomal Complex Induces Alternative Splicing Events and Lymphoma Cell Necrosis. Cell chemical biology. 26(5). 756–764.e6. 5 indexed citations

Magee, Daniel, Zoran Gatalica, Adam Stark, et al.. (2018). Poly-ligand profiling (PLP) to differentiate pancreatic cancer patients who benefit from gemcitabine+evofosfamide versus gemcitabine+placebo treatment.. Journal of Clinical Oncology. 36(15_suppl). 12067–12067. 2 indexed citations

Thomson, Stuart, Elizabeth Buck, Erica Ullman, et al.. (2012). Abstract B56: Insights into the role of Epithelial to Mesenchymal transition (EMT) as an important mechanism of drug-resistance to molecular targeted therapies. Clinical Cancer Research. 18(10_Supplement). B56–B56. 1 indexed citations

Falcón, Beverly L., Sharon Barr, Prafulla C. Gokhale, et al.. (2011). Reduced VEGF Production, Angiogenesis, and Vascular Regrowth Contribute to the Antitumor Properties of Dual mTORC1/mTORC2 Inhibitors. Cancer Research. 71(5). 1573–1583. 80 indexed citations

O’Connor, Matthew, Amrita Mohan, Suzanne C. Brady, et al.. (2011). Abstract 4463: OSI-027, a dual mTORC1/mTORC2 inhibitor, induces autophagy in cancer cells. Cancer Research. 71(8_Supplement). 4463–4463. 1 indexed citations

Buck, Elizabeth, Prafulla C. Gokhale, Susan Koujak, et al.. (2010). Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer. Molecular Cancer Therapeutics. 9(10). 2652–2664. 183 indexed citations

Buck, Elizabeth, Prafulla C. Gokhale, Susan Koujak, et al.. (2010). OR13,78 Compensatory activation of insulin receptor (IR) upon inhibition of insulin-like growth factor-1 receptor (IGF-1R): Rationale for co-targeting IGF-1R and IR in cancer. Growth Hormone & IGF Research. 20. S35–S35. 2 indexed citations

10.

Buck, Elizabeth, Alexandra Eyzaguirre, Maryland Rosenfeld-Franklin, et al.. (2008). Feedback Mechanisms Promote Cooperativity for Small Molecule Inhibitors of Epidermal and Insulin-Like Growth Factor Receptors. Cancer Research. 68(20). 8322–8332. 164 indexed citations

11.

Barr, Sharon, Stuart Thomson, Elizabeth Buck, et al.. (2008). Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. Clinical & Experimental Metastasis. 25(6). 685–693. 169 indexed citations

12.

Eyzaguirre, Alexandra, Elizabeth Buck, Kenneth K. Iwata, John D. Haley, & Mark Miglarese. (2008). Mechanisms of resistance to EGFR tyrosine kinase inhibitors: implications for patient selection and drug combination strategies. Targeted Oncology. 3(4). 235–243. 4 indexed citations

13.

Barr, Sharon, Suzanne Russo, Elizabeth Buck, et al.. (2007). The EGFR antagonist, erlotinib, combined with a small molecule inhibitor of IGF-1R acts synergistically to inhibit proliferation and induce apoptosis in ovarian and HNSCC cells. Molecular Cancer Therapeutics. 6. 3 indexed citations

14.

Buck, Elizabeth, Alexandra Eyzaguirre, Stuart Thomson, et al.. (2007). Differential effects for small molecule versus antibody inhibitors of EGFR: Erlotinib, but not the neutralizing antibody C225, achieves inhibition of the EGFR-HER3-Akt signaling cascade. Molecular Cancer Therapeutics. 6. 1 indexed citations

15.

Miglarese, Mark, Rich Woessner, Shelley Allen, et al.. (2006). ARRY-649, a member of a novel class of Eg5 kinesin inhibitors. Journal of Clinical Oncology. 24(18_suppl). 13045–13045. 3 indexed citations

16.

Miglarese, Mark & Robert Carlson. (2006). Development of new cancer therapeutic agents targeting mitosis. Expert Opinion on Investigational Drugs. 15(11). 1411–1425. 34 indexed citations

17.

Halaban, Ruth, et al.. (1998). Release of cell cycle constraints in mouse melanocytes by overexpressed mutant E2F1E132, but not by deletion of p16INK4A or p21WAF1/CIP1. Oncogene. 16(19). 2489–2501. 31 indexed citations

18.

Halaban, Ruth, Mark Miglarese, Yoel Smicun, & Susana Puig. (1998). Melanomas, from the cell cycle point of view (Review).. International Journal of Molecular Medicine. 1(2). 419–25. 26 indexed citations

19.

Miglarese, Mark, et al.. (1996). Differential Regulation of c-Myb-induced Transcription Activation by a Phosphorylation Site in the Negative Regulatory Domain. Journal of Biological Chemistry. 271(37). 22697–22705. 47 indexed citations

20.

Miglarese, Mark, et al.. (1994). The protein tyrosine kinase substrate cortactin is differentially expressed in murine B lymphoid tumors.. PubMed. 9(7). 1989–97. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact